GuidoLancmanMD

Physician

Dr. Lancman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Icahn School of Medicine at Mount Sinai (Bronx)Residency, Internal Medicine, 2015 - 2018
Icahn School of Medicine at Mount SinaiClass of 2015

PubMed

Comparing the clinical trial efficacyreal-world effectiveness of treatments for multiple myeloma: a population-based study.
Alissa Visram, Kelvin Kar-Wing Chan, Hsien Seow, Gregory Pond, Anastasia Gayowsky
Haematologica. 2025-01-01
2 citations
Bispecific antibodies in the treatment of multiple myeloma.
Anup Joseph Devasia, Ajai Chari, Guido Lancman
Blood Cancer Journal. 2024-09-12
Recommendations for the effective use of T-cell-redirecting therapies: a Canadian consensus statement.
Guido Lancman, Kevin Song, Darrell White, Tina Crosbie, Ismail Sharif
Frontiers in Oncology. 2024-01-01

Abstracts/Posters

Impact of Primary Antibacterial Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients
Guido Lancman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Intravenous Immunoglobulin May Prevent Severe Infections Associated with Anti-BCMA Therapy for Multiple MyelomaSeptember 30th, 2023
IV Immunoglobulin May Cut Infection Risk of Anti-BCMA Agents for MyelomaOctober 1st, 2023
IVIg Reduces Infection Rate in Multiple Myeloma Patients Receiving Anti-BCMA TherapyOctober 7th, 2023